Yinghong Shi

20PUBLICATIONS

34CO-AUTHORS

Molecular targetsHaematological tumoursGene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (20)

Sort by Publication Date:

|Jun 02, 2026

Combined MEK1/2 and Autophagy Inhibition Suppresses Tumor Growth via STING-Mediated Type I Interferon Response in iCCA.

|Dec 19, 2025

DNMT2-m5C-ACLY Axis Promotes Lenvatinib Resistance in Hepatocellular Carcinoma Through Histone Acetylation-Mediated Notch Pathway.

Shiguang Yang, Jie Li, Shengwei Mao

|Nov 24, 2025

Targeting CREB3L2-mediated lipid metabolism overcomes lenvatinib resistance and attenuates the progression of hepatocellular carcinoma.

Shiguang Yang, Shaoqing Liu, Jie Li

|Jul 22, 2025

Metabolism archetype cancer cells induce protumor TREM2<sup>+</sup> macrophages via oxLDL-mediated metabolic interplay in hepatocellular carcinoma.

Tianhao Chu, Guiqi Zhu, Zheng Tang

|May 02, 2025

Targeting HMGB2 acts as dual immunomodulator by bolstering CD8<sup>+</sup> T cell function and inhibiting tumor growth in hepatocellular carcinoma.

Wei-Feng Qu, Gui-Qi Zhu, Rui Yang

|Mar 06, 2025

Sintilimab plus bevacizumab followed by resection in intermediate-stage hepatocellular carcinoma: a phase Ib clinical trial with biomarker analysis.

Hui-Chuan Sun, Xiao-Dong Zhu, Zi-Yi Wang

Pageof 4

Frequent Collaborators

Jian Zhou

Guiqi Zhu

Jia Fan

Weiren Liu

Yichao Bu

ZhenBin Ding

Qing Chen

Jia-Cheng Lu

Xiao-Dong Zhu

Wei-Feng Qu

Frequent Collaborators

Jian Zhou

Guiqi Zhu

Jia Fan

Weiren Liu